General Announcement::HYPHENS PHARMA HAS INKED EXCLUSIVE LICENSING DEAL OF USTEKINUMAB BIOSIMILAR

Issuer & Securities

Issuer/ Manager
HYPHENS PHARMA INTERNATIONAL LIMITED
Securities
HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
14-Dec-2021 12:22:39
Status
New
Announcement Sub Title
HYPHENS PHARMA HAS INKED EXCLUSIVE LICENSING DEAL OF USTEKINUMAB BIOSIMILAR
Announcement Reference
SG211214OTHRCYIW
Submitted By (Co./ Ind. Name)
Lim See Wah
Designation
Executive Chairman and Chief Executive Officer
Description (Please provide a detailed description of the event in the box below)
Please refer to the attached.

This announcement has been reviewed by the Sponsor, SAC Capital Private Limited. ("Sponsor").

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn, who can be contacted at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, Telephone: +65 6232 3210.

Attachments

Hyphens Pharma MR for Ustekinumab.pdf
Total size =693K